Changes in benign prostatic hyperplasia management in Valencia: A real-world evidence analysis

被引:0
|
作者
Navarro-Perez, J. [1 ]
Alcina, E. Lopez [2 ]
Perez, J. Calabuig [3 ]
Munto, F. Brotons [4 ]
Martinez, A. [5 ]
Vallejo, L. [6 ]
Jimenez, J. [6 ]
机构
[1] Univ Valencia, Hosp Clin Univ Valencia, Ctr Invest Biomed Red Epidemiol & Salud Publ CIBER, Inst Invest Sanitaria INCLIVA, Valencia, Spain
[2] Consorcio Hosp Gen Univ Valencia, Serv Urol, Valencia, Spain
[3] Conselleria San Universal & Salud Publ, Serv Anal Sistemas Informac Sanitaria, Valencia, Spain
[4] Ctr Salud Trinitat, Valencia, Spain
[5] GlaxoSmithKline, Dept Med, Madrid, Spain
[6] GlaxoSmithKline, Dept Market Access, Madrid, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2024年 / 48卷 / 06期
关键词
Benign prostatic hyperplasia; Training program; Primary care; Real-world study; URINARY-TRACT SYMPTOMS; GUIDELINES;
D O I
10.1016/j.acuro.2023.11.006
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction and objectives: A training program was developed to increase general practitioners' engagement in the optimal management of benign prostatic hyperplasia (BPH). The goal of this study was to evaluate changes in BPH management after the implementation of a training program. Material and methods: This observational retrospective cohort study was conducted between 2019 and 2020. Aggregated data were analyzed in 3 evaluation periods (2010, 2012 and 2015), addressing quality indicators for diagnosis, treatment, and treatment outcomes. Results: Overall, 118,795 patients who presented any data points were included. All quality indicators (number of IPSS and PSA determinations) increased between the first period and the last. Combination (alpha-blocker + 5-ARI) therapy was increasingly prescribed during the study periods whereas the proportion of prescriptions for single -agent alpha-blocker showed no significant differences among the periods analyzed. However, the total number of patients eligible for combination therapy who actually received this treatment was low in all periods (7.5, 17.9, and 20.1%, in 2010, 2012, and 2015, respectively). The outcome indicators revealed a decrease in referrals to the Urology unit mostly among newly diagnosed patients. Even though the proportion of patients who underwent BPH-related surgeries increased significantly from the first to the second period, the number of surgeries remained stable between the second and third periods. Conclusions: The training program had a generally positive impact on the management of BPH patients in primary care, but the overall study period may be insufficient to show an effect on some outcome indicators such as the number of surgeries. (c) 2024 The Authors. Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of AEU. This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:461 / 469
页数:9
相关论文
共 50 条
  • [21] Real-world assessment and characteristics of men with benign prostatic hyperplasia (BPH) in primary care and urology clinics in Spain
    Maria Molero, Jose
    Minana, Bernardino
    Manuel Palacios-Moreno, Juan
    Tellez Martinez-Fornes, Miguel
    Lorite Mingot, David
    Agra Rolan, Alfonso
    Carreno, Agata
    Cuervo Pinto, Rafael
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2020, 74 (11)
  • [22] ANATOMIC CHANGES IN BENIGN PROSTATIC HYPERPLASIA
    WASSERMAN, NF
    RADIOLOGY, 1995, 197 : 495 - 495
  • [23] Lasers are superfluous for the surgical management of benign prostatic hyperplasia in the developing world
    Gupta, Narmada P.
    Anand, Ajay
    INDIAN JOURNAL OF UROLOGY, 2009, 25 (03) : 413 - 414
  • [24] Management of benign prostatic hyperplasia with silodosin
    Yamanishi, Tomonori
    Mizuno, Tomoya
    Kamai, Takao
    Yoshida, Ken-Ichiro
    Sakakibara, Ryuji
    Uchiyama, Tomoyuki
    RESEARCH AND REPORTS IN UROLOGY, 2009, 1 : 1 - 7
  • [25] Medical management of benign prostatic hyperplasia
    Haile, Eiftu S.
    Sotimehin, Ayodeji E.
    Gill, Bradley C.
    CLEVELAND CLINIC JOURNAL OF MEDICINE, 2024, 91 (03) : 163 - 170
  • [26] Phytotherapy in the management of benign prostatic hyperplasia
    Lowe, FC
    UROLOGY, 2001, 58 (6A) : 71 - 76
  • [27] Optimizing the management of benign prostatic hyperplasia
    Elterman, Dean S.
    Barkin, Jack
    Kaplan, Steven A.
    THERAPEUTIC ADVANCES IN UROLOGY, 2012, 4 (02) : 77 - 83
  • [28] THE LASER IN THE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA
    DELAROSETTE, JJMCH
    FITZPATRICK, JM
    WORLD JOURNAL OF UROLOGY, 1995, 13 (02) : 73 - 73
  • [29] NONOPERATIVE MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA
    LEPOR, H
    JOURNAL OF UROLOGY, 1989, 141 (06): : 1283 - 1289
  • [30] Management of benign prostatic hyperplasia (BPH)
    Jokisch J.-F.
    Herlemann A.
    Weinhold P.
    Magistro G.
    Stief C.G.
    Gratzke C.
    MMW - Fortschritte der Medizin, 2017, 159 (9) : 58 - 64